Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 6, 2001, Pages 567-606

  Szebeni, J ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Allergy; Anaphylactoid reaction; Anaphylatoxins; Blood substitutes; Cancer chemotherapy; Complement; Cremophor EL; Liposomes; Micelles; Poloxamers; Radiocontrast agents; Taxol

Indexed keywords

ACETRIZOIC ACID; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CHELATING AGENT; COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3B RECEPTOR DERIVATIVE; CONTRAST MEDIUM; CREMOPHOR; DOXORUBICIN; DRUG CARRIER; FLUOSOL DA; HYDRAZINONICOTINAMIDE PHOSPHATIDYLETHANOLAMINE CONJUGATE PLUS POLYETHYLENE GLYCOL; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IODAMIDE; IODIXANOL; IOHEXOL; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C5A; MONOCLONAL ANTIBODY C5G1.1; NICOTINAMIDE; PACLITAXEL; PERFLUOROTRIBUTYLAMINE; POLOXAMER; POLYOXYETHYLENE; RICINOMACROGOL; SOLVENT; TP 10; TP 20; UNCLASSIFIED DRUG;

BASOPHIL; CELL ACTIVATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; LABORATORY TEST; MAST CELL; MICELLE; NONHUMAN; PREDICTION; REACTION ANALYSIS; REVIEW; RISK FACTOR; SYMPTOM;

EID: 0035660629     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i6.50     Document Type: Review

References (234)

1. Drug allergy and reactions
2. Incidence of adverse drug reactions in hospitalized patients A meta-analysis of prospective studies
3. Predictive capacity of histamine release for the diagnosis of drug allergy
4. Classification of allergic reactions responsible for drug hypersensitivity reactions
5. Gell Coombs's classification: Is it still valid?
6. Mediators of immediate hypersensitivity reactions
7. In vitro complement activation by ragweed allergen extract in the sera of ragweed allergic and non-allergic persons
8. Ragweed allergy: Correlation between skin reactivity and in vitro complement activation
9. The severity of clinical symptoms in ragweed-allergic patients is related to the extent of ragweed-induced complement activation in their sera
10. Comparative study of the complement-activating and specific IgE-binding properties of ragweed pollen allergens
11. Allergic diseases
12. Allergy and mechanism of hypersensitivity
13. Hypersensitivity
14. Effector mechanisms of immunoglobulin E-initiated immune reactions
15. Over-reactions of the immune system
16. Control of the complement system
17. Pulmonary infiltrates following administration of paclitaxel
18. Hypersensitvity reactions to the taxanes paclitaxel and docetaxel
19. Cardiac disturbances during the administration of Taxol
20. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma
21. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
22. Structure and function of anaphylatoxins
23. Effects of anaphylatoxins on circulation
24. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody
25. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction
26. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins
27. The complement system in extracorporeal circulation
28. Complement activation in cardiopulmonary bypass with special reference to anaphylatoxin production in membrane and bubble oxygenators
29. Inflammatory response to cardiopulmonary bypass
30. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro
31. Acute symptoms during and between hemodialysis: The relative role of speed duration and biocompatibility of dialysis
32. Individual differences in biocompatibility responses to hemodialysis
33. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation
34. A study of the effects of extracorporeal circulation on the immunologic system of humans
35. Proinflammatory cytokine release during pediatric cardiopulmonary bypass: Influence of centrifugal and roller pumps
36. Use of liposomes as injectable drug delivery systems
37. Overview of liposomes
38. Liposomes opportunities in drug delivery
39. Liposome-based patents for use in the pharmaceutical industry
40. Liposomal anthracyclines: From basics to clinical approval of PEGylated liposomal doxorubicin
41. Intravenous infusion of high doses of liposomes containing NSC 251635 a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data
42. Cardiopulmonary toxicity after liposomal amphotericin B infusion
43. Ventricular arrhythmias with conventional and liposomal amphotericin
44. Anaphylactic reactions to liposomal amphotericin
45. Allergic reactions and other rare side effects of liposomal amphotericin
46. Liposomal and lipid-based formulations of amphotericin B
47. Anaphylactic reaction to liposomal amphotericin (AmBisome)
48. Amphotericin B-not so terrible
49. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary Phase I studies
50. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
51. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
52. Safety assessment: DoxilR (Doxorubicin HC1 liposome injection) in refractory AIDS-related Kaposi's sarcoma
53. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
54. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors
55. ®)
56. The role of complement activation in hypersensitivity reactions to polyethyleneglycol-coated liposomes
57. Complement-mediated acute effects of liposome-encapsulated hemoglobin
58. Immune response of a liposomal model membrane
59. Antibody binding and complement fixation by a liposomal model membrane
60. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten
61. Release of trapped marker from liposomes by the action of purified complement components
62. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
63. Activation of human complement by liposomes: A model for membrane activation of the alternative pathway
64. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma
65. Assay of complement activity in human serum using large unilamellar liposome
66. Activation of human complement by liposomes: Serum factor requirement for alternative pathway activation
67. Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenyl-aminocaproyl-dipalmitoylphosphatidylethanolamine
68. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes
69. Liposomes as model membrane systems for immune attack II The interaction of complement and K cell populations with immobilized liposomes
70. Influence of vesicle size on complement-dependent immune damage to liposomes
71. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement
72. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: Evidence for anti-lipid antibodies and alternative pathway activation
73. The interaction of liposomes with the complement system
74. Administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man
75. Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease
76. Complement activation by pegylated liposomal doxorubicin (Doxil) in cancer patients: Association with hypersensitivity reactions
77. In vivo applications of PEG-liposomes: Unexpected observations
78. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: Clinical evaluation
79. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)
80. The complement system
81. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
82. Clinical studies of liposome-encapsulated doxorubicin
83. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma
84. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids
85. Strategy for in vitro evaluation of the interactions between biomaterials and complement system
86. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement
87. Studies upon the toxicity of polyethylene glycol coated lipid vesicles: Acute hemodynamic effects pyrogenicity and complement activation
88. Pharmacological-toxicological experts report Caelix (Stealth liposomal doxorubicin HC1)
89. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres
90. Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles
91. Modification of the copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres
92. In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres
93. Re-establishing the long circulatory behavior of poloxamine-coated particles after repeated intravenous administration: Applications in cancer drug delivery and imaging
94. Influence of pluronic F-68 on dissolution and bioavailability characteristics of multiple-layer pellets of nifedipine for controlled release delivery
95. Biodegradable nanoparticles as a delivery system for cyclosporine: Preparation and characterization
96. Radiolabelled biodegradable microspheres for lung imaging
97. Properties of cremophor EL micelles probed by fluorescence
98. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
99. Pharmaceutical properties of paclitaxel and their effects on preparation and administration
100. Formation of complement-activating particles in aqueous solutions of Taxol: Possible role in hypersensitivity reactions
101. Artificial blood emulsifiers
102. 13C-NMR evidence on amphiphile lifetime in reverse (waterin-oil) micelles formed by a poloxamer block copolymer
103. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells
104. Untersuchungen uber Cremophor EL
105. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
106. Quantification of Cremophore EL in human plasma samples using colorimetric dye-binding microassay
107. Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32) an adriamycin analog
108. Hypersensitivity reactions induced by etoposide
109. Allergic reactions associated with cremophor-containing antineoplastics
110. Acute vasomotor response - A reaction to etoposide
111. Alergic reactions to cytotoxic drugs - An update
112. Effect of subchronic corn oil gavage on the acute toxicity of orally administered bromodichloromethane
113. Capture of stealth nanoparticles by the body's defences
114. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis
115. Influence of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man
116. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%
117. Cardiorespiratory consequences of fluorocarbon reactions in dogs
118. A Phase I trial of Taxol given as 3-hour infusions every 21 days
119. Hypersensitivity reactions from Taxol
120. Taxol: The first of the taxanes an important new class of antitumor agents
121. Clinical pharmacology of Taxol
122. Clinical toxicities encountered with paclitaxel (Taxol)
123. The clinical pharmacology of paclitaxel (Taxol)
124. Successful re-treatment with Taxol after major hypersensitivity reactions
125. Clinical toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review
126. Clinical pharmacology and metabolism of Taxol (paclitaxel): Update 1993
127. Paclitaxel (Taxol)
128. Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions
129. Successful parenteral desensitization to paclitaxel
130. Paclitaxel hypersensitivity revisited
131. The development and utility of the taxane class of antimicrotubule chemotherapy agents
132. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles
133. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
134. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
135. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration
136. Paclitaxel hypersensitivity reactions related to bee sting allergy
137. Alternative formulations of paclitaxel
138. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)
139. New active paclitaxel amino acids derivatives with improved water solubility
140. Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype
141. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal
142. Suspected anaphylactic reaction to Cremophor EL
143. Anaphylactoid reactions associated with parenteral cyclosporine use: Possible role of Cremophor EL
144. Histamine release in dogs by Cremophor EL and its derivatives: Oxyethylated oleic acid is the most effective constituent
145. The effects of cremophor EL in the anaesthetized dog
146. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin
147. Mechanism of anaphylactoid reactions: Improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine
148. Direct vasoconstrictor effects of sandimmune (cyclosporine A) are mediated by its vehicle cremophor EL: Inhibition by the thromboxane A2/prostaglandin endoperoxide receptor antagonist ifetroban
149. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: The causative role of improper dissolution of Cremophor EL
150. Immunological biocompatibility in blood substitutes
151. Pharmacokinetics of RheothRx injection in healthy male volunteers
152. Effects of RheothRx on mortality morbidity left ventricular function and infarct size in patients with acute myocardial infarction
153. The adjuvant activity of nonionic block polymer surfactants II antibody formation and inflammation related to the structure of triblock and octablock copolymers
154. Modulation of antigen presentation and host mediators by block copolymer adjuvants
155. Nonionic block polymers: New preparations and review of the mechanism of action
156. The role of complement in experimental silicosis
157. Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles
158. Enhancement of crystal induced neutrophil responses by opsonisation of calcium pyrophosphate dihydrate crystal
159. Mechanism of complement activation by crystalline cholesterol
160. Variation of complement activation in human serum by poloxamer 188 (Pluronic-F68)
161. Influence of block copolymers on the adsorption of plasma proteins to microspheres
162. PEG-coated nanospheres: Surface optimization and therapeutic applications
163. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators
164. The non-ionic surfactant Poloxamer 188 (RheothRx) increases plasma and whole blood viscosity
165. Inhibition of polymer-induced red blood cell aggregation by poloxamer 188
166. Pluronic F-68 inhibits agonist-induced platelet aggregation in human whole blood in vitro
167. Randomized controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction
168. Effect of poloxamer 188 on collateral blood flow myocardial infarct size and left ventricular function in a canine model of prolonged (3-hour) coronary occlusion and reperfusion
169. Anaphylactoid reactions to radiocontrast materia
170. Prophylactic antihistamines in the management of radiographic contrast reactions
171. Allergy grand rounds anaphylactoid reactions to radiocontrast material
172. Radiocontrast reactions
173. Contrast media reactions
174. Development of contrast media idiosyncrasy in the dog
175. Activation of serum complement by contrast media
176. The effect of epsilon-aminocaproic acid and prednisolone on the activation of the complement system due to x-ray contrast agents in rats in vitro
177. The complement-activating action of modem x-ray contrast agents
178. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media
179. Comparative study of the adverse effects of various radiographic contrast media including ioversol a new low-osmolarity medium. II. The complement system and endothelial cells
180. Complement activation and histamine release following administration of roentgen contrast media
181. Suppression of alternative complement pathway activity by radiographic contrast media
182. Changes in complement and coagulation factors in a patient suffering a severe anaphylactoid reaction to injected contrast material: Some considerations of pathogenesis
183. Fulminant pulmonary edema following intravenous administration of radiocontrast media
184. Requirement for C5a in lung vascular injury following thermal trauma to rat skin
185. Anaphylatoxin generation in multisystem organ failure
186. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome
187. Production of acute pulmonary injury by leukocytes and activated complement
188. Pathophysiology of the adult respiratory distress syndrome What have we learned from human studies?
189. The role of the complement system in the pathogenesis of multiple organ failure in shock
190. Cascade system activation in shock
191. Adult respiratory distress syndrome following thoracic trauma
192. Angiography and complement activation Evidence for generation of C3a anaphylatoxin by intravascular contrast agents
193. Adverse reactions to intravascular administration of contrast media
194. Radiographic contrast media and the coagulation and complement systems
195. Complement and coagulation: Causative considerations in contrast catastrophies
196. Case report: Recurrent anaphylactic shock to radiographic contrast media. Evidence supporting an exceptional IgE-mediated reaction
197. Complement activation in human serum by liposome-encapsulated hemoglobin: The role of natural anti-phospholipid antibodies
198. Complement activation in vitro by the red blood cell substitute liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1
199. Release of sulfidoleukotrienes in vitro: Its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid
200. Allergic and pseudoallergic reactions to non-narcotic analgesics
201. Immediate-type reactions to pyrazole derivatives: Results of skin tests and antibody determinations
202. Biologically active peptides of complement. Techniques and significance of C3a and C5a measurements
203. Mechanisms of leukocyte regulation by complement-derived factors
204. A mechanism of action for anaphylatoxin C3a stimulation of mast cells
205. Identification of chemical respiratory allergens: Dose response relationship in the mouse IgE test
206. Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens
207. Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice
208. Limitation of complement activation by perfluorocarbon emulsions: Superiority of lecithin-emulsified preparations
209. Use of finger-prick human blood samples as a more convenient way for in-vitro screening of modified hemoglobin blood substitutes for complement activation: A preliminary report
210. Activation and control of complement inflammation and infection associated with the use of biomedical polymers
211. Components of complement in patients with immediate hypersensitivity
212. Glucocorticoid-induced elevations of Cl-esterase inhibitor: A mechanism for protection against lethal dose range contrast challenge in rabbits
213. Effect of elevated C1-esterase inhibitor concentrations on white blood cell-endothelium interactions: A potential mechanism for steroid protection in contrast material reactions
214. Controlling the complement system in inflammation
215. Novel complement inhibitors
216. Therapeutic inhibition of the complement system
217. Therapeutic inhibition of the complement system Y2K update
218. The complement system: An old story or target of new therapeutic approaches
219. Complement inhibitors: A resurgent concept in anti-inflammatory therapeutics
220. C1-Esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema
221. Activation systems in contrast idiosyncrasy
222. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system
223. Actions of anaphylatoxin on circulation and respiration of the guinea pig
224. Signaling in mast cells
225. Allergy and pseudoallergy: An overview of basic mechanisms
226. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms
227. Pseudoallergy or nonallergic hypersensitivity
228. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children